Press releases

Cash position: +€9.9m at June 30, 2018 compared to +€4.9m at December 31, 2017 thanks to the reinforcement of shareholders' equity Half-...

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...

The General Meeting approved the contribution in kind of the BIOVERTIS (parent company of MORPHOCHEM) shares and options and the issuance...

HEBELYS ® is a natural active ingredient produced by the fermentation of Sphingomonas , a bacterium belonging to the DEINOVE proprietary...

MORPHOCHEM's MCB3837 antibiotic compound aims to treat severe gastrointestinal infections caused by Clostridium difficile , a priority...

Deinove scientific platform has designed an exclusive Deinococcus fermentation process to deliver the first pure Phytoene for application...

Cash position: +€6.6m at June 30, 2017 compared to +€9.3m at December 31, 2016. Half-year net loss of DEINOVE Group (composed of DEINOVE...

Hervé Brailly, co-founder and executive of Innate Pharma SA [IPH], one of the world's leading immuno-oncology specialists and one of the...

Cash position of €9.3 million, and net loss down 1% to €6.3 million Strategic focus on high value-added applications in the healthcare,...

Four directors of international standing and experts in pharmaceutical industry and antibiotics join the Board of Directors: Bernard Fanget...